← ANI PHARMACEUTICALS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $128.6m |
$176.8m
+37.49%
|
$201.6m
+13.99%
|
$206.5m
+2.47%
|
$208.5m
+0.93%
|
$216.1m
+3.67%
|
$316.4m
+46.38%
|
$486.8m
+53.87%
|
$614.4m
+26.20%
|
$883.4m
+43.78%
|
$978.4m
+10.76%
|
|
| Cost of Goods and Services Sold | $48.8m |
$79.0m
+62.02%
|
$73.0m
-7.60%
|
$63.2m
-13.52%
|
$87.2m
+38.01%
|
$100.6m
+15.44%
|
$138.8m
+37.94%
|
$181.5m
+30.79%
|
$250.2m
+37.85%
|
$341.3m
+36.41%
|
$387.4m
+13.50%
|
|
| Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization | $48.8m |
$79.0m
+62.02%
|
$73.0m
-7.60%
|
$63.2m
-13.52%
|
$87.2m
+38.01%
|
$100.6m
+15.44%
|
$138.8m
+37.94%
|
$181.5m
+30.79%
|
$250.2m
+37.85%
|
$341.3m
+36.41%
|
$387.4m
+13.50%
|
|
| Gross Profit (Calculated) | $79.8m |
$97.8m
+22.50%
|
$128.6m
+31.43%
|
$143.4m
+11.54%
|
$121.3m
-15.39%
|
$115.5m
-4.77%
|
$177.6m
+53.73%
|
$305.3m
+71.90%
|
$364.2m
+19.28%
|
$542.1m
+48.85%
|
— | |
| Research and Development Expense | $2.9m | $9.1m | $15.4m | $19.8m | $16.0m | $11.4m | $22.3m | $34.3m | $44.6m | $51.7m | $49.9m | |
| Selling, General and Administrative Expense | $27.8m | $31.6m | $44.1m | $55.8m | $65.0m | $84.3m | $124.0m | $161.7m | $249.6m | $317.7m | $324.8m | |
| Amortization of Intangible Assets | $21.4m | $26.7m | $31.7m | $40.2m | $39.9m | $41.8m | $49.5m | $52.3m | $60.3m | $82.5m | — | |
| Restructuring and Related Cost, Incurred Cost | — | — | — | — | — | — | $5.7m | $1.1m | $0 | $0 | — | |
| Operating expenses: | ||||||||||||
| Operating Income (Loss) | $20.1m |
$28.3m
+41.09%
|
$35.4m
+24.82%
|
$16.4m
-53.76%
|
($16.0m)
-197.95%
|
($39.8m)
-148.46%
|
($35.3m)
+11.33%
|
$47.0m
+233.13%
|
$584k
-98.76%
|
$111.1m
+18922.77%
|
$130.5m
+17.47%
|
|
| Interest Expense, Debt | $11.3m | $11.3m | $14.9m | $13.5m | $9.5m | $11.9m | $28.4m | $32.5m | $33.6m | $32.6m | $16.5m | |
| Gain (Loss) Related to Litigation Settlement | — | — | — | — | — | ($8.8m) | — | $0 | — | — | — | |
| Other Nonoperating Income (Expense) | ($74k) | $55k | ($550k) | ($228k) | ($494k) | ($4.3m) | $670k | ($159k) | ($4.0m) | $1.9m | — | |
| Interest Income (Expense), Nonoperating, Net | ($11.3m) | ($12.0m) | ($14.8m) | ($13.0m) | ($9.5m) | ($11.9m) | ($28.1m) | ($26.9m) | ($17.6m) | ($20.1m) | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | — | — | — | — | — | ($24.6m) | $103.6m | $142.6m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $8.7m | $16.3m | $20.1m | $3.2m | ($26.0m) | ($56.1m) | ($62.7m) | $19.9m | ($22.2m) | $95.8m | $142.6m | |
| Current Income Tax Expense (Benefit) | $13.0m | $13.9m | $9.7m | $6.2m | $9.8m | $3.3m | $467k | $12.7m | $17.8m | $2.7m | $34.3m | |
| Income Tax Expense (Benefit) | $4.7m | $17.4m | $4.6m | ($2.9m) | ($3.4m) | ($13.5m) | ($14.8m) | $1.1m | ($3.7m) | $17.5m | $34.3m | |
| Net Income (Loss) Attributable to Parent | $3.9m |
($1.1m)
-127.35%
|
$15.5m
+1539.96%
|
$6.1m
-60.67%
|
($22.5m) | ($42.6m) | ($47.9m) | $18.8m | ($18.5m) | $78.3m |
$99.6m
+27.14%
|
|
| Net Income (Loss) Available to Common Stockholders, Basic | $3.9m |
($1.1m)
-127.50%
|
$15.3m
+1525.65%
|
$6.0m
-60.91%
|
($22.5m)
-475.99%
|
($42.8m)
-89.79%
|
($49.5m)
-15.72%
|
$17.2m
+134.64%
|
($20.1m)
-217.45%
|
$77.2m
+483.08%
|
$99.6m
+29.05%
|
|
| Preferred Stock Dividends, Income Statement Impact | — | — | — | — | — | $190k | $1.6m | $1.6m | $1.6m | $1.2m | $1.2m | |
| Undistributed Earnings (Loss) Allocated to Participating Securities, Basic | — | — | — | — | — | — | — | $1.7m | $0 | $7.0m | — | |
| Earnings Per Share, Basic | $0.34 | ($0.09) | $1.31 | $0.51 | ($1.88) | ($3.40) | ($3.05) | $0.86 | ($1.04) | $3.50 | $4.83 | |
| Earnings Per Share, Diluted | $0.34 | ($0.09) | $1.30 | $0.50 | ($1.88) | ($3.40) | ($3.05) | $0.85 | ($1.04) | $3.32 | $4.59 | |
| Weighted Average Number of Shares Outstanding, Basic | 11.4m | 11.5m | 11.7m | 11.8m | 12.0m | 12.6m | 16.3m | 18.0m | 19.3m | 20.1m | 20.7m | |
| Weighted Average Number of Shares Outstanding, Diluted | 11.6m | 11.5m | 11.8m | 12.0m | 12.0m | 12.6m | 16.3m | 18.2m | 19.3m | 21.2m | 22.0m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | $108.5m | $148.5m | $166.2m | $190.2m | $224.5m | $255.9m | $351.7m | $439.8m | $613.8m | $772.3m | — | |
| Goodwill, Impairment Loss | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $767k | |
| Other Interest and Dividend Income | — | — | — | — | — | — | — | — | $6.3m | $4.9m | — | |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | $3.9m | ($1.1m) | $15.5m | $6.1m | ($22.5m) | ($42.6m) | ($47.9m) | $18.8m | ($18.5m) | $78.3m | — |